Zobrazeno 1 - 10
of 91
pro vyhledávání: ''
Autor:
Yuping Dong, Robert Hamlin, Daniel Gaudet, Erik S.G. Stroes, Lesley J. Burgess, Robert Pordy, Nagwa Khilla, Shazia Ali, C. Ebenbichler, Seth J. Baum, Robert S. Rosenson, Vladimir Son
Publikováno v:
New England journal of medicine, 383(24), 2307-2319. Massachussetts Medical Society
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the
Autor:
Samuel Klein, Richard I. Stein, Jeramie D. Watrous, Rob Knight, J. Christopher Eagon, Jun Yoshino, Mohit Jain, Mihoko Yoshino, Dominic N. Reeds, Brandon D. Kayser, Shaina R. Eckhouse, Bruce W. Patterson, Kenneth B. Schechtman
Publikováno v:
The New England journal of medicine, vol 383, iss 8
N Engl J Med
N Engl J Med
BACKGROUND: Some studies have suggested that in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on metabolic function that are independent of weight loss. METHODS: We evaluated metabolic regulators of glucose homeostasis
Autor:
Kolb, Martin, Raghu, Ganesh, Wells, Athol U, Behr, Jürgen, Richeldi, Luca, Schinzel, Birgit, Quaresma, Manuel, Stowasser, Susanne, INSTAGE Trial Investigators, Benjamin Bondue, Bondue, Benjamin, Martinez, Fernando J
Publikováno v:
The New England journal of medicine, 379 (18
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusio
Autor:
Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J.
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of
Autor:
Nevens, F, Andreone, P, Mazzella, G, Strasser, S, Bowlus, C, Drenth, J, Pockros, P, Regula, J, Beuers, U, Trauner, M, Jones, D, Floreani, A, Hohenester, S, Luketic, V, Shiffman, M, van Erpecum, K, Vargas, V, Vincent, C, Hirschfield, G, Shah, H, Hansen, B, Lindor, K, Marschall, H, Kowdley, K, Hooshmand Rad, R, Marmon, T, Sheeron, S, Pencek, R, Macconell, L, Pruzanski, M, Shapiro, D. Collaborator: Carbone, INVERNIZZI, PIETRO
Publikováno v:
New England Journal of Medicine, 375(7), 631-643. Massachussetts Medical Society
New England journal of medicine, 375(7), 631-643. Massachussetts Medical Society
New England Journal of Medicine, 375(7), 631. Massachussetts Medical Society
The New England Journal of Medicine, 375, 631-43
The New England Journal of Medicine, 375, 7, pp. 631-43
New England journal of medicine, 375(7), 631-643. Massachussetts Medical Society
New England Journal of Medicine, 375(7), 631. Massachussetts Medical Society
The New England Journal of Medicine, 375, 631-43
The New England Journal of Medicine, 375, 7, pp. 631-43
none 32 BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or dea
Autor:
William J, Sandborn, Brian G, Feagan, Douglas C, Wolf, Geert, D'Haens, Severine, Vermeire, Stephen B, Hanauer, Subrata, Ghosh, Heather, Smith, Matthew, Cravets, Paul A, Frohna, Richard, Aranda, Sheila, Gujrathi, Allan, Olson
Publikováno v:
New England journal of medicine, 374(18), 1754-1762. Massachussetts Medical Society
Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract. We
Autor:
Michael S. Saag, David Wong, Rachel Baden, Liyun Ni, John G. McHutchison, Anne F Luetkemeyer, Douglas T. Dieterich, Curtis Cooper, Mark S. Sulkowski, Paul E. Sax, E.J. Gane, Javier O Morales-Ramirez, Susanna Naggie, Phillip S. Pang, William J. Towner, Peter Ruane, Dushyantha Jayaweera, Catherine A.M. Stedman, Luisa M. Stamm, Kimberly A. Workowski, Hadas Dvory-Sobol, Jorge Santana-Bagur, Polina German, Amy E. Colson, Norbert Bräu, Jenny C. Yang, Pablo Tebas, Kristen M. Marks
Publikováno v:
New England Journal of Medicine. 373:705-713
Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need.We conducted a multicenter, single-group, open-label study involving patients coinfected with HIV-1
Autor:
Anne Chew, David M. Barrett, Yolanda D. Mahnke, Bruce L. Levine, Noelle Frey, David L. Porter, Pamela A. Shaw, J. Joseph Melenhorst, Carl H. June, Zhaohui Zheng, Susan R. Rheingold, Nancy Bunin, Shannon L. Maude, Vanessa E. Gonzalez, David T. Teachey, Stephan A. Grupp, Simon F. Lacey, Angela Shen, Richard Aplenc
Publikováno v:
New England Journal of Medicine. 371:1507-1517
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission
Autor:
Sandborn, William J., Su, Chinyu, Sands, Bruce E., D'Haens, Geert R., Vermeire, Séverine, Schreiber, Stefan, Danese, Silvio, Feagan, Brian G., Reinisch, Walter, Niezychowski, Wojciech, Friedman, Gary, Lawendy, Nervin, Yu, Dahong, Woodworth, Deborah, Mukherjee, Arnab, Zhang, Haiying, Healey, Paul, Panés Díaz, Julià, OCTAVE Induction 1, OCTAVE Induction 2, OCTAVE Sustain Investigators., Guardiola, Jordi
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
New England journal of medicine, 376(18), 1723-1736. Massachussetts Medical Society
Universidad de Barcelona
New England journal of medicine, 376(18), 1723-1736. Massachussetts Medical Society
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2d0d357d18521a403fbcc3cdf5d19d
http://hdl.handle.net/2445/189961
http://hdl.handle.net/2445/189961
Autor:
Xavier Forns, B. Bernstein, Eric M. Yoshida, Thomas Berg, Stefan Zeuzem, Mitchell L. Shiffman, Roger Trinh, Barbara Da Silva-Tillmann, Heiner Wedemeyer, Christophe Hézode, Thomas Podsadecki, Christine Collins, Kosh Agarwal, Campbell Andrew L, Sandra S. Lovell, Kris V. Kowdley, Fred Poordad
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor A